Shin Nippon Biomedical Laboratories, Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, company now expects Revenue of JPY 25,000 million compared to JPY 24,000 million which is previously announced, Operating profit to be JPY 5,460 million compared to JPY 5,260 million, Profit attributable to owners of parent to be JPY 5,310 million compared to JPY 7,000 million and Profit per share to be JPY 127.54 compared to JPY 168.13 as previously expected.